Format

Send to

Choose Destination
Trends Endocrinol Metab. 2005 May-Jun;16(4):190-7.

Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.

Author information

1
Paediatric Endocrinology Section, University Children's Hospital, Hoppe-Seyler-Strasse 1, D-72076 Tübingen, Germany. michael.ranke@med.uni-tuebingen.de

Abstract

Insulin-like growth factor I (IGF-I) has many potential therapeutic uses because of its varied effects--growth promotion, insulin-like influence on glucose metabolism, and neuroprotection resulting from cell-proliferative and antiapoptotic properties--but they have not been investigated systematically in clinical situations. The growth-promoting effect of recombinant human IGF-I (rhIGF-I) in the extensively studied growth hormone insensitivity syndrome (GHIS; Laron syndrome) signifies an endocrine role for the GH-IGF system. The metabolism of (adult) patients with severe insulin resistance is improved by rhIGF-I, which--together with insulin therapy--also improves metabolic control in type 1 and 2 diabetes. Further studies on IGF-I metabolic effects and growing understanding of the IGF-I-IGF-binding protein system could open new therapeutic avenues.

PMID:
15860416
DOI:
10.1016/j.tem.2005.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center